Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine.
Federica VernuccioCarlo MessinaValeria MerzRoberto CannellaMassimo MidiriPublished in: Diagnostics (Basel, Switzerland) (2021)
The incidence and mortality of pancreatic ductal adenocarcinoma are growing over time. The management of patients with pancreatic ductal adenocarcinoma involves a multidisciplinary team, ideally involving experts from surgery, diagnostic imaging, interventional endoscopy, medical oncology, radiation oncology, pathology, geriatric medicine, and palliative care. An adequate staging of pancreatic ductal adenocarcinoma and re-assessment of the tumor after neoadjuvant therapy allows the multidisciplinary team to choose the most appropriate treatment for the patient. This review article discusses advancement in the molecular basis of pancreatic ductal adenocarcinoma, diagnostic tools available for staging and tumor response assessment, and management of resectable or borderline resectable pancreatic cancer.
Keyphrases
- palliative care
- locally advanced
- lymph node
- liver metastases
- advanced cancer
- rectal cancer
- quality improvement
- squamous cell carcinoma
- healthcare
- minimally invasive
- pet ct
- high resolution
- coronary artery bypass
- case report
- atrial fibrillation
- coronary artery disease
- photodynamic therapy
- percutaneous coronary intervention
- mesenchymal stem cells
- fluorescence imaging
- clinical evaluation